Infertility results

Triptorelin - clinical data

Triptorelin (GnRH agonist; decapeptide with MW 1’311 Da) for down-regulation of infertility patients in the pituitary gland prior to follicle stimulation with FSH. Current treatment is a daily subcutaneous injection of 0.1 mg/day.
Preclinical in vitro data suggest reaching therapeutically relevant blood concentration.

The Pantec Biosolutions triptorelin patch shows excellent pharmacokinetic results with achieved blood levels in humans that were factors above therapeutically needed values.
Inter-patient variability was very low and >60% of the triptorelin became bio-available.

Further pharmacodynamic and a pivotal studies are in progress to make triptorelin ready for commercialisation.

FSH (Follicle stimulating Hormone) – preclinical data

The currently mostly used FSH infertility treatment is a daily subcutaneous injection of 150 to 300 I.U. of the protein hormone over 10-12 days with the goal to stimulate egg cell (oocyte) maturisation in down-regulated women.
Follicle-stimulating hormone (FSH, 30 kDa) is a hormone synthesized and secreted by gonadotropes in the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the human body.



FSH in vitro human skin data show permeation rates that suggest sufficient clinical results. Preliminary studies hint at blood levels comparable to subcutaneous blood levels of FSH.